These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 23563416)

  • 1. Building for big pharma.
    Giniatullina A; Boorsma M; Mulder GJ; van Deventer S
    Nat Biotechnol; 2013 Apr; 31(4):284-7. PubMed ID: 23563416
    [No Abstract]   [Full Text] [Related]  

  • 2. Value creation and sharing among universities, biotechnology and pharma.
    Edwards MG; Murray F; Yu R
    Nat Biotechnol; 2003 Jun; 21(6):618-24. PubMed ID: 12776145
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharma in-licensing 2007--cost versus paucity.
    Williams M
    Curr Opin Investig Drugs; 2007 Jan; 8(1):17-24. PubMed ID: 17263181
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharma Law Europe - Eighth Annual Conference.
    Indraccolo AD; Chapman C
    IDrugs; 2008 Nov; 11(11):807-10. PubMed ID: 18988124
    [No Abstract]   [Full Text] [Related]  

  • 5. The premium of a big pharma license deal.
    O'Connell KE; Frei P; Dev KK
    Nat Biotechnol; 2014 Jul; 32(7):617-9. PubMed ID: 25004224
    [No Abstract]   [Full Text] [Related]  

  • 6. Bashing Big Pharma.
    Van Way CW
    Mo Med; 2019; 116(2):80-82. PubMed ID: 31040484
    [No Abstract]   [Full Text] [Related]  

  • 7. Financial Times Global Pharmaceutical & Biotechnology Conference 2009.
    Scattereggia J
    IDrugs; 2010 Jan; 13(1):26-9. PubMed ID: 20024844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. South Africa vs. big pharma.
    Birmingham K
    Nat Med; 2001 Apr; 7(4):390. PubMed ID: 11283645
    [No Abstract]   [Full Text] [Related]  

  • 9. Big Pharma and social responsibility--the Access to Medicine Index.
    Hogerzeil HV
    N Engl J Med; 2013 Sep; 369(10):896-9. PubMed ID: 24004116
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharma spends big to buy influence.
    Nat Med; 2010 Mar; 16(3):243. PubMed ID: 20208486
    [No Abstract]   [Full Text] [Related]  

  • 11. Minimizing leakage of value from R&D alliances.
    Jones A
    Nat Rev Drug Discov; 2007 Sep; 6(9):711-9. PubMed ID: 17703230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Big pharma swallows biotech's pride.
    Huggett B
    Nat Biotechnol; 2008 Sep; 26(9):955-6. PubMed ID: 18779785
    [No Abstract]   [Full Text] [Related]  

  • 13. Anxious wait for patients and big pharma.
    Kirby T
    Lancet Neurol; 2015 Mar; 14(3):246-7. PubMed ID: 25728435
    [No Abstract]   [Full Text] [Related]  

  • 14. Deals landscape: notable deals in the pharmaceutical industry in the first quarter of 2008.
    Shumoogam J; Al-Shamahi A
    IDrugs; 2008 May; 11(5):351-5. PubMed ID: 18465677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In-licensing as a business model.
    Schafer DP
    Nat Biotechnol; 2002 Jul; 20 Suppl():BE36-9. PubMed ID: 12089585
    [No Abstract]   [Full Text] [Related]  

  • 16. Bill 102: deal or no deal for big pharma.
    Rasky H
    Health Law Can; 2007 May; 27(4):73-84. PubMed ID: 17580795
    [No Abstract]   [Full Text] [Related]  

  • 17. India's patent case victory rattles Big Pharma.
    Chatterjee P
    Lancet; 2013 Apr; 381(9874):1263. PubMed ID: 23589911
    [No Abstract]   [Full Text] [Related]  

  • 18. Big pharma under the spotlight.
    Farham B
    S Afr Med J; 2013 May; 103(6):352. PubMed ID: 23725968
    [No Abstract]   [Full Text] [Related]  

  • 19. It's time to consider a patent reprieve for COVID vaccines.
    Nature; 2021 Apr; 592(7852):7. PubMed ID: 33785920
    [No Abstract]   [Full Text] [Related]  

  • 20. Andrew Witty: the acceptable face of big pharma? Interviewed by Rebecca Coombes.
    Witty A
    BMJ; 2013 Mar; 346():f1458. PubMed ID: 23468295
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.